Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose: This meta-analysis evaluates and compares the diagnostic accuracy of [F]FDG PET/CT and [F]FDG PET/MRI in detecting breast cancer recurrence.
Methods: A search was conducted across PubMed, Web of Science, and Embase databases up to June 10, 2025, to identify studies evaluating the diagnostic performance of [F]FDG PET/CT and/or [F]FDG PET/MRI in breast cancer recurrence. Sensitivity and specificity were calculated using the DerSimonian and Laird method with Freeman-Tukey double arcsine transformation. The Quality Assessment for Studies of Diagnostic Accuracy-2 (QUADAS-2) guidelines were employed to perform the quality evaluation.
Results: Seventeen studies involving 1,450 patients were included. At the lesion level, the sensitivity of [F]FDG PET/CT was 0.97 (95% CI: 0.91-1.00), with a specificity of 0.79 (95% CI: 0.58-0.94). [F]FDG PET/MRI showed a sensitivity of 0.95 (95% CI: 0.91-0.99) and specificity of 0.87 (95% CI:0.75-0.95). Both modalities demonstrated similar sensitivity ( = 0.71) and specificity ( = 0.66). At the patient level, the sensitivity of [F]FDG PET/CT was 0.93 (95% CI: 0.88-0.96), with a specificity of 0.87 (95% CI: 0.80-0.93). [F]FDG PET/MRI showed a sensitivity of 0.99 (95% CI: 0.94-1.00) and specificity of 0.98 (95% CI, 0.90-1.00). Both modalities demonstrated similar sensitivity ( = 0.07) and specificity ( = 0.06).
Conclusion: [F]FDG PET/CT and [F]FDG PET/MRI exhibit comparable sensitivity and specificity in detecting breast cancer recurrence at both the lesion and patient levels. However, high heterogeneity warrants further head-to-head studies to strengthen the evidence and provide more comprehensive insights.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12354408 | PMC |
| http://dx.doi.org/10.3389/fmed.2025.1602415 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
PET/CT imaging of the late-gestation fetal brain in pregnant rats: A proof-of-concept study.
J Cereb Blood Flow Metab
September 2025
Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.
Preclinical PET studies offer the opportunity to elucidate molecular mechanisms underlying early neurodevelopment with minimal invasiveness. We demonstrated the feasibility of fetal brain PET in four pregnant rats ( = 42 fetuses). [F]FDG uptake in rat fetuses was readily visualized by PET imaging.
View Article and Find Full Text PDF[F]FDG-PET provides insights into the liver-brain axis and confirms SUV as a surrogate for MR in a mouse model of liver fibrosis.
Nucl Med Biol
September 2025
Department of Nuclear Medicine, Hannover Medical School, Germany. Electronic address:
Purpose: The liver-brain axis regulates metabolic homeostasis, with glucose metabolism playing a key role. Liver dysfunction, such as fibrosis, may impact brain metabolism and consequently, brain function. Positron emission tomography (PET) imaging provides a non-invasive approach to study glucose metabolism in both organs.
View Article and Find Full Text PDFUtility of [Tc]Tc-tilmanocept, an immunosuppressive macrophage functional imaging agent in melanoma patients receiving checkpoint inhibitor treatment: a feasibility study.
Cancer Immunol Immunother
September 2025
Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital, CHUV/UNIL, 1011, Lausanne, Switzerland.
Background: Immunotherapy is a mainstay in the treatment of patients with advanced melanoma. Yet, resistance mechanisms exist, and tumour-associated macrophages (TAMs), particularly the M2-like phenotype, are associated with poorer outcomes, with CD206 serving as their specific marker. We present the first human SPECT/CT study to visualize CD206 + TAMs in patients undergoing immunotherapy and compare the findings to clinical outcomes (NCT04663126).
View Article and Find Full Text PDFArtificial intelligence-assisted assessment of metabolic response to tebentafusp in metastatic uveal melanoma: a long axial field-of-view [F]FDG PET/CT study.
Eur J Nucl Med Mol Imaging
September 2025
Department of Dermatology and National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany.
Purpose: Tebentafusp has emerged as the first systemic therapy to significantly prolong survival in treatment-naïve HLA-A*02:01 + patients with unresectable or metastatic uveal melanoma (mUM). Notably, a survival benefit has been observed even in the absence of radiographic response. This study aims to investigate the feasibility and prognostic value of artificial intelligence (AI)-assisted quantification and metabolic response assessment of [F]FDG long axial field-of-view (LAFOV) PET/CT in mUM patients undergoing tebentafusp therapy.
View Article and Find Full Text PDFThe Complementary Roles of F-Fluorocholine and F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in an Evaluation of A Patient With Parathyroid Carcinoma: A Case Report.
Mol Imaging Radionucl Ther
September 2025
University Clinical Center of Serbia, Center for Nuclear Medicine with PET, Belgrade, Serbia.
Fluorine-fluorocholine (F-FCH) is a radiopharmaceutical used in primary hyperparathyroidism. The data about its utility in malignancies other than prostate and hepatocellular carcinoma is limited. We present the case of a patient who was referred for F-FCH positron emission tomography/computed tomography (PET/CT) due to the persistently elevated parathormone and calcium levels following total thyroidectomy with left lower parathyroidectomy for parathyroid carcinoma (PTC).
View Article and Find Full Text PDF